Semaglutide shows significant weight loss and health benefits in four-year obesity study

FHS
May 15, 2024
2:16 am

A study in Nature Medicine evaluated the effects of semaglutide on weight and anthropometric outcomes in adults with obesity but without diabetes, finding significant weight loss and improved health metrics over four years. The study also highlighted the safety and tolerability of semaglutide across different BMI categories.

Innovative AI model uses YouTube vlogs to identify depression signs early

An innovative depression detection model that leverages audiovisual features from YouTube vlogs.

November 8, 2023

After the Lykos debacle, what’s next for psychedelic therapies? – Pharmaceutical Technology

The latest attempt at FDA approval for MDMA has failed, but those working with psychedelics maintain confidence that the therapy will ultimately see success. Image:

September 16, 2024

PROs Support Practice-Changing RUBY Trial in Endometrial Cancer

The buzz created by two phase III studies testing immunotherapy in advanced or recurrent endometrial cancer at the Society of Gynecologic Oncology (SGO) annual meeting

June 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.